Form 4 Filing for Kiniksa Pharmaceuticals International, plc

This filing details transactions by Barry D. Quart, a director at Kiniksa Pharmaceuticals International, plc. On April 6, 2026, Mr. Quart acquired 6,901 Class A Ordinary Shares through the exercise of a vested share option at a price of $14.33 per share. This option exercise was part of a 10b5-1 plan. Following the acquisition, his post-transaction shares were 19,447. Concurrently, he disposed of 6,901 Class A Ordinary Shares at a weighted average price of $50.00 per share, resulting in 12,546 shares remaining. The option exercise and share disposal were executed under a 10b5-1 trading plan. The option, exercisable until June 28, 2031, was acquired on September 11, 2025. The weighted average sale price reflects multiple trades at prices between $50.00 and $50.015.